1. Home
  2. AUTL

AUTL

Autolus Therapeutics plc

Logo Autolus Therapeutics plc

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Founded: 2014 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 1.2B IPO Year: 2018
Target Price: $8.50 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.20 EPS Growth: N/A
52 Week Low/High: $1.61 - $7.45 Next Earning Date: 05-02-2024
Revenue: $1,698,000 Revenue Growth: -73.30%
Revenue Growth (this year): 2505.95% Revenue Growth (next year): 173.41%

Share on Social Networks: